Johnson & Johnson Co DRC

JNJ · BA · Healthcare / Drug Manufacturers - General

$28,720-100.00 (-0.35%)

Close Sep 21, 2026 · end-of-day

Market Stats

Previous Close$28,820

Open$28,540

Day Range$28,540 – $29,180

52-Week Range$17,010 – $29,820

Volume10.75K

Market Cap$334.49T

P/E (TTM)10.70

Forward P/E7.41

EPS$2,595.56

Dividend Yield1.82%

Beta0.23

50-Day Avg$28,321.2

200-Day Avg$24,725.2

Price History

Open in new tab

Loading price history…

About

Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as oncology, immunology, neuroscience, pulmonary hypertension, infectious diseases, and cardiovascular and metabolism distributed through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use. The MedTech segment provides a portfolio of products used in the surgery, orthopedic, cardiovascular, and vision fields distributed through wholesalers, hospitals and retailers, and used in the professional fields by physicians, nurses, hospitals, eye care professionals and clinics. This segment also offers products and enabling technologies that support joint reconstruction, trauma, spine, sports related injuries, and others, as well as open, laparoscopic, and robotic surgical procedures; instrumentation, energy devices, stapling systems, wound closure, biosurgery products, and digital and robotic technologies; breast aesthetics and reconstruction; contact lenses under the ACUVUE brand; intraocular lenses for cataract surgery, and other products used in cataract and refractive procedures under the TECNIS brand. The company was founded in 1886 and is based in New Brunswick, New Jersey.

Company Details

Sector: Healthcare
Industry: Drug Manufacturers - General
CEO: Mr. Joaquin Duato
Employees: 138.20K
Headquarters: One Johnson & Johnson Plaza, New Brunswick, NJ, United States, 08933, Argentina
Website: https://www.jnj.com

Leadership

Mr. Joaquin DuatoCEO & Chairman · b. 1963
Mr. Joseph James Wolk CPAExecutive VP & CFO · b. 1967
Dr. John C. Reed M.D., Ph.D.Executive Vice President of Innovative Medicine and R&D · b. 1958
Mr. Timothy SchmidExecutive VP & Worldwide Chairman of MedTech · b. 1970
Mr. Robert J. Decker Jr.Controller & Chief Accounting Officer · b. 1973
Mr. James SwansonExecutive VP & Chief Information Officer · b. 1966
Mr. Ryan KoorsVice President of Investor Relations
Mr. Dirk BrinckmanChief Compliance Officer
Ms. Elizabeth Forminard J.D.Executive VP & Chief Legal Officer · b. 1971
Ms. Kristen Blair MulhollandExecutive VP & Chief Human Resources Officer · b. 1967

Financials

Income Statement

Line item	2018-12-31	2019-12-31	2020-12-31	2021-12-31	2022-12-31	2023-12-31	2024-12-31	2025-12-31
Total Revenue	$81.58B	$82.06B	$82.58B	$93.78B	$94.94B	$85.16B	$88.82B	$94.19B
Cost of Revenue	$27.09B	$27.56B	$28.43B	$29.86B	$31.09B	$26.55B	$27.47B	$30.26B
Gross Profit	$54.49B	$54.50B	$54.16B	$63.92B	$63.85B	$58.61B	$61.35B	$63.94B
Operating Income	$21.18B	$20.97B	$19.91B	$24.55B	$23.70B	$22.01B	$21.25B	$25.60B
EBITDA	$25.93B	$24.66B	$23.93B	$30.35B	$26.61B	$23.32B	$24.78B	$41.05B
Net Income	$15.30B	$15.12B	$14.71B	$20.88B	$17.94B	$35.15B	$14.07B	$26.80B
R&D	$10.78B	$11.36B	$12.16B	$14.71B	$15.39B	$15.09B	$17.23B	$14.66B
Interest Expense	$1.00B	$318.00M	$201.00M	$183.00M	$276.00M	$772.00M	$755.00M	$971.00M

Balance Sheet

Line item	2018-12-31	2019-12-31	2020-12-31	2021-12-31	2022-12-31	2023-12-31	2024-12-31	2025-12-31
Total Assets	$152.95B	$157.73B	$174.89B	$182.02B	$187.38B	$167.56B	$180.10B	$199.21B
Total Liabilities	$93.20B	$98.26B	$111.62B	$108.00B	$110.57B	$98.78B	$108.61B	$117.67B
Total Equity	$59.75B	$59.47B	$63.28B	$74.02B	$76.80B	$68.77B	$71.49B	$81.54B
Cash	$18.11B	$17.30B	$13.98B	$14.49B	$14.13B	$21.86B	$24.11B	$19.71B
Net Debt	$12.37B	$10.39B	$21.28B	$19.26B	$25.53B	$7.47B	$12.53B	$28.22B

Cash Flow

Line item	2018-12-31	2019-12-31	2020-12-31	2021-12-31	2022-12-31	2023-12-31	2024-12-31	2025-12-31
Operating Cash Flow	$22.20B	$23.42B	$23.54B	$23.41B	$21.19B	$20.28B	$24.27B	$24.53B
Investing Cash Flow	$-3.17B	$-6.19B	$-20.82B	$-8.68B	$-12.37B	-	-	-
Financing Cash Flow	$-18.51B	$-18.02B	$-6.12B	$-14.05B	$-8.87B	$-9.47B	$-3.13B	$-5.54B
Capital Expenditure	$3.67B	$3.50B	$3.35B	$3.65B	$4.01B	$4.54B	$6.21B	$5.22B
Free Cash Flow	$18.53B	$19.92B	$20.19B	$19.76B	$17.18B	$15.74B	$18.06B	$19.31B
Dividends Paid	$9.49B	$9.92B	$10.48B	$11.03B	$11.68B	$11.86B	$11.82B	$12.38B

Key Statistics & Ratios

Market Cap: $334.49T
Enterprise Value: $1025.07T
Trailing P/E: 10.70
Forward P/E: 7.41
PEG Ratio: 0.99
Price / Sales: 3415.68
Price / Book: 2.69
EPS: $2,595.56
Book Value: $3,587.3
Revenue (TTM): $97.93B
Gross Profit (TTM): $66.73B
EBITDA: $34.87B
Profit Margin: 21.48%
Operating Margin: 29.19%
Return on Equity: 25.74%
Return on Assets: 8.60%
Shares Outstanding: 12.05B
Shares Float: 35.91B
Beta: 0.23
Dividend Yield: 1.82%
Dividend Rate: $511.66
Payout Ratio: 20.26%

Dividends

20194×

$0.19Nov 25, 2019$0.19Aug 26, 2019$0.19May 24, 2019$0.18Feb 25, 2019

20183×

$0.18Nov 26, 2018$0.18Aug 27, 2018$0.17Feb 26, 2018

20172×

$0.17Aug 25, 2017$0.16Feb 24, 2017

20164×

$0.16Nov 18, 2016$0.16Aug 19, 2016$0.16May 20, 2016$0.15Feb 19, 2016

20154×

$0.15Nov 20, 2015$0.15Aug 21, 2015$0.15May 21, 2015$0.09Feb 20, 2015

20144×

$0.14Nov 21, 2014$0.14Aug 22, 2014$0.14May 22, 2014$0.13Feb 21, 2014

20133×

$0.13Nov 22, 2013$0.13Aug 23, 2013$0.13May 23, 2013